



Sushma Bharadwaj, MD

Clinical Assistant Professor, Medicine - Blood & Marrow Transplantation

CLINICAL OFFICE (PRIMARY)

- **Blood and Marrow Transplantation**

900 Blake Wilbur Drive

Stanford, CA 94304

Tel (650) 723-0822 Fax (650) 725-8950

ACADEMIC CONTACT INFORMATION

- **Alternate Contact**

Kim Burnham - Administrative Associate

Email kimburn@stanford.edu

Bio

BIO

Dr. Bharadwaj is fellowship-trained in blood and marrow transplantation, cellular therapy, hematology, and oncology. She is an instructor in the Stanford School of Medicine Department of Medicine, Division of Blood & Marrow Transplantation and Cellular Therapy.

Dr. Bharadwaj focuses her expertise on diagnosing and treating cancer in blood and bone marrow. For each patient, she develops a personalized, comprehensive, and compassionate care plan. In her diverse experience as a physician and scientist, she has served as an internal medicine doctor, hospitalist, hematologist, oncologist, and blood and marrow transplantation specialist. Dr. Bharadwaj has a degree in clinical research and is currently conducting clinical trials in transplant and cellular therapy.

She has participated in research studies of advances in therapy for chronic lymphocytic leukemia, melanoma, and breast cancer. She has co-authored articles published in *Leukemia* and *Lymphoma* and elsewhere. Topics include advances in cell transplantation. She also co-wrote the chapter on genome-driven personalized cancer therapy in the book *Precision Medicine in Oncology*.

Dr. Bharadwaj has made presentations at meetings of the American Society of Hematology, American Society of Clinical Oncology, and other associations.

Subjects include racial, demographic, and socioeconomic disparities in the treatment of patients with acute myeloid leukemia.

Dr. Bharadwaj is a member of the American Society for Transplantation and Cellular Therapy, American Society of Hematology, and American Society of Clinical Oncology.

CLINICAL FOCUS

- Cancer > Blood and Marrow Transplant
- Cancer > Hematology > Leukemia - Acute and Chronic
- Cancer > Lymphoma

- Hematology
- Leukemia
- Lymphoma

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Blood & Marrow Transplantation

HONORS AND AWARDS

- ASTCT Clinical Research Training Course Scholar, ASTCT (2022)
- Organizational Excellence Award, South Zone Pharmacology Conference, Mangalore, India

PROFESSIONAL EDUCATION

- Board Certification: Hematology, American Board of Internal Medicine (2021)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2021)
- Fellowship: Stanford University Bone Marrow Transplant Fellowship (2021) CA
- Fellowship: Cook County Health Hematology Oncology Fellowship (2020) IL
- Residency: John H Stroger Jr Hospital of Cook County Internal Medicine Residency (2013) IL
- Internship: University of Illinois College of Medicine at Peoria (2011) IL
- Medical Education: Kasturba Medical College Mangalore (2006) India

Research & Scholarship

CLINICAL TRIALS

- Expanded Access Protocol (EAP) for Nonconforming (NC) Afi-cel, Recruiting

Publications

PUBLICATIONS

- **Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucef Toxicity Reduces the Total Duration of CRS and ICANS.** *Blood advances*
Wang, W. L., Lee, D., Cheung, E., Jensen, A., Rana, M. S., Goyal, A., Hamilton, M. P., Ghalehsari, N., Latchford, T., Scott, B. J., Mallampet, J., Heng, E., Khan, et al
2026
- **AI-Quantified Patient Frailty Predicts Clinical Response to CAR-T**
Smith, C. J., Fettahoglu, A., Johnston, A., Smith, B. R., Mikkilineni, L., Sidana, S., Weng, W., Frank, M., Dahiya, S., Smith, M., Chaudhari, A., Miklos, D. B., Boutin, et al
ELSEVIER SCIENCE INC.2026
- **Impact of IMWG Frailty and Nutritional Biomarkers on Outcomes in MM Pts Undergoing ASCT**
Uzun, D., Zhang, A., Austin, R., Yeung, S. B., Kondapally, Y. R., Jensen, A., Hovanky, V., Rana, M., Shizuru, J. A., Arai, S., Rezvani, A. R., Bharadwaj, S., Lowsky, et al
ELSEVIER SCIENCE INC.2026
- **The Relationship of Baseline and Longitudinal Frailty and Inflammatory Biomarkers with CAR-T Treatment Outcomes in Relapsed Refractory Myeloma**
Yeung, S. B., Kondapally, Y. R., Uzun, D., Zhang, A., Austin, R., Jensen, A., Hovanky, V., Rana, M., Shizuru, J. A., Arai, S., Rezvani, A. R., Bharadwaj, S., Lowsky, et al
ELSEVIER SCIENCE INC.2026
- **Impact of Baseline and Dynamic IMWG Simplified Frailty Scores on Outcomes after CAR T-cell and Bispecific Antibody Therapy in Multiple Myeloma**

Zhang, A., Uzun, D., Yeung, S. B., Kondapally, Y. R., Austin, R., Jensen, A., Hovanky, V., Rana, M., Shizuru, J. A., Arai, S., Rezvani, A. R., Bharadwaj, S., Lowsky, et al
ELSEVIER SCIENCE INC.2026

- **Impact of Social Determinants of Health on Access to CAR-T Therapy and Outcomes in Multiple Myeloma Patients**
Rana, M., Kaveh, N., Jensen, A., Kennedy, V. E., Weng, W., Smith, M., Shiraz, P., Jandir, N., Latchford, T. M., Frank, M., Bharadwaj, S., Dahiya, S., Miklos, et al
ELSEVIER SCIENCE INC.2026
- **Characterization and Outcomes of Switching Tacrolimus to Sirolimus in Patients with Transplant-Associated Thrombotic Microangiopathy**
Kennedy, V. E., Lauer, M., Shiraz, P., Arai, S., Johnston, L., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Lowsky, R., Meyer, E. H., Mikkilineni, L., Muffly, et al
ELSEVIER SCIENCE INC.2026
- **Impact of Complete Response on Long-Term Survival in Patients With Relapsed or Refractory Large B-cell Lymphoma: A CIBMTR Prospective Study and SLR/Meta-Analysis.** *Transplantation and cellular therapy*
Ghobadi, A., Anagnostou, T., Azzi, J., Hamadani, M., Logan, B., Ahmed, S., Bharadwaj, S., Baird, J. H., Jacobson, C., Locke, F. L., Ulrickson, M., Reagan, P. M., Hemmer, et al
2026
- **Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas.** *Leukemia & lymphoma*
Klebaner, D., Park, N. J., Marar, M., Frank, M., Hiniker, S. M., Hoppe, R. T., Schroers-Martin, J., Advani, R. H., Alizadeh, A. A., Bharadwaj, S., Miklos, D., Dahiya, S., Binkley, et al
2025: 1-8
- **Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation**
Molina, A., Bubb, Q., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, E., Mikkilineni, L., Lowsky, et al
ELSEVIER.2025: 2494-2495
- **Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (rLBCL): Interim results from a Phase 1b study**
Lee, D., Rodrigues, K., Rana, M., Kozy, K., Salazar, S., Jensen, A., Desai, M., Mallampet, J., Lohman, C., Huang, Y., Kang, X., Tian, F., Mutter, et al
ELSEVIER.2025: 671-672
- **Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL**
Spiegel, J., Oak, J., Rana, M., Jensen, A., Lee, D., Nguyen-Mau, S., Kong, K., Bornheimer, S., Mikkilineni, L., Muffly, L., Sidana, S., Weng, W., Bharadwaj, et al
ELSEVIER.2025: 5882-5883
- **Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia**
Huang, J., Voutsinas, J., Khaire, N., Pizzuti, V., Shune, L., Lei, M., Fonseca, R., Din, M., Skarbnik, A., Mian, A., Bharadwaj, S., Alsougi, A., Wankel, et al
ELSEVIER.2025: 798-799
- **Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study**
Villar-Prados, A., Kim, P., Sutherland, K., Negrin, R., Arai, S., Frank, M., Johnston, L., Lowsky, R., Miklos, D., Muffly, L., Dahiya, S., Rezvani, A., Sidana, et al
ELSEVIER.2025: 111-112
- **Allogeneic hematopoietic cell transplantation in acute myeloid leukemia not in complete remission: outcomes and prognostic factors in a contemporary cohort.** *Blood cancer journal*
Elias, S., Brown, S., Eagini, O., Walji, M., Homsy, S., Velayati, A., Devlin, S., Ponce, D. M., Kennedy, V., Bharadwaj, S., Shiraz, P., Jakubowski, A. A., Papadopoulos, et al
2025; 15 (1): 208
- **CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity**

- Srinagesh, H., Kramer, A., Hamilton, M., Su, Y., Kozy, K., Jackson, L., Brown, A., Denoble, K., Mavroukakis, S., Lohman, C., Cunanan, K., Agarwal, N., Bharadwaj, et al
ELSEVIER.2025: 4159-4160
- **Redefining post-CD19 CAR T-cell surveillance with ctDNA: Real-world insights from post- axi-cel and liso-cel therapy**
Ananth, S., Mallampet, J., Chang, B., Agarwal, N., Kong, K., Sahaf, B., Serrato, J., Kirsch, I., Jacob, A., Simmons, H., Lee, L., Mackall, C., Weng, et al
ELSEVIER.2025: 941-942
 - **Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post-CAR-T therapy**
Rana, M., Ghalehsari, N., Jensen, A., Lee, D., Park, N., Goyal, A., Hashmi, A., Wang, W., Heng, E., Velayati, A., Dhapola, G., Huang, Y., Sahaf, et al
ELSEVIER.2025: 397-398
 - **Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT**
Jeyakumar, N., Torres, N., Godbole, S., Yamamoto, F., Zhang, B., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, et al
ELSEVIER.2025: 2525-2526
 - **Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL**
Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., Srinagesh, H., Danley, L., Ramakrishnan, A., Daghigh, H., Huang, Y., Dhapola, G., Siddiqui, et al
ELSEVIER.2025: 514-515
 - **From response to rupture: Evaluating GI perforation after CD19 CAR-T in LBCL**
Velayati, A., Rana, M., Jensen, A., Lee, D., Ghalehsari, N., Goyal, A., Latchford, T., Wang, W., Heng, E., Weng, W., Smith, M., Bharadwaj, S., Frank, et al
ELSEVIER.2025: 2771-2772
 - **Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)**
Rana, M., Jensen, A., Velayati, A., Hovanky, V., Muffly, L., Sahaf, B., Iberri, D., Liedtke, M., Bharadwaj, S., Kennedy, V., Arai, S., Shiraz, P., Weng, et al
ELSEVIER.2025: 4586-4587
 - **CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias. *Research square***
Hamilton, M. P., Phillips, N., Noordenbos, T., Boegeholz, J., Sugio, T., Sworder, B. J., Alig, S. K., Good, Z., Schroers-Martin, J. G., Tamaresis, J., Esfahani, M. S., Lu, Y., Olsen, et al
2025
 - **Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of CAR-T Therapy in Relapsed or Refractory Large B-Cell Lymphoma**
Goyal, A., Bharadwaj, S., Lau, E., Jensen, A., Hamilton, M., Lee, C., Sahaf, B., Syal, S., Patil, S., Latchford, T., Dahiya, S.
CIG MEDIA GROUP, LP.2025: S1051-S1052
 - **Immune Reconstitution, Vaccine Protection, and Infectious Complications Following BCMA-Targeted CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma**
Moscvin, M., Goyal, A., Jensen, A., Epstein, D., Hovanky, V., Mikkilineni, L., Bennett, L., Latchford, T., Arai, S., Bharadwaj, S., Frank, M., Dahiya, S., Muffly, et al
CIG MEDIA GROUP, LP.2025
 - **The Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Referred from Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024. *Transplantation and cellular therapy***
Uzun, D., Paul, J. M., Jensen, A., Tamaresis, J., Domingo, W., Arai, S., Ventura, F. A., Rocha, J., Bennett, L., Jones, A., Bharadwaj, S., Johnston, L., Lowsky, et al
2025
 - **Allogeneic hematopoietic cell transplantation for acute leukemia patients not in complete remission**
Elias, S., Brown, S., Eagini, O., Walji, M., Homsy, S., Velayati, A., Devlin, S., Ponce, D., Kennedy, V., Bharadwaj, S., Shiraz, P., Jakubowski, A. A., Papadopoulos, et al
LIPPINCOTT WILLIAMS & WILKINS.2025

- **Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy.** *Blood advances*
Ananth, S., Torres, N. E., Sahaf, B., Mikkilineni, L., Fernandez-Pol, S., Salmi, D., Negrin, R. S., Shiraz, P., Smith, M., Bharadwaj, S., Weng, W. K., Kennedy, V. E., Dahiya, et al
2025
- **Lisocabtagene Maraleucel for Richter's Transformation-A Case Series.** *EJHaem*
Smith, C. J., Goyal, A., Smith, B. R., Lee, D., Jensen, A., Alexander, J., Smith, M., Frank, M., Dahiya, S., Miklos, D., Bharadwaj, S.
2025; 6 (2): e270011
- **Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.** *Blood*
Meyer, E., Pavlova, A., Villar-Prados, A., Bader, C. S., Xie, B., Muffly, L., Kim, P., Sutherland, K. C., Bharadwaj, S., Dahiya, S., Frank, M. J., Arai, S., Johnston, et al
2025
- **Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL.** *Cancer discovery*
Su, Y. J., Kramer, A. M., Hamilton, M. P., Agarwal, N., Srinagesh, H. K., Baird, J. H., Sahaf, B., Kuo, A., Ehlinger, Z. J., Desai, M. H., Rietberg, S. P., Tunuguntla, R., Patel, et al
2025
- **A 17-Year Experience of a Large Dedicated Fellowship in Blood and Marrow Transplantation and Cellular Therapy: A Blueprint for Modern Day Training Program.** *Journal of cancer education : the official journal of the American Association for Cancer Education*
Bharadwaj, S., Lowsky, R., Mikkilineni, L., Smith, M., Weng, W. K.
2024
- **Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice.** *Bone marrow transplantation*
Chin, M. M., Tamaresis, J. S., Johnston, L. J., Lowsky, R., Meyer, E., Muffly, L., Shiraz, P., Frank, M. J., Rezvani, A. R., Bharadwaj, S., Weng, W. K., Shizuru, J. A., Arai, et al
2024
- **Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma**
Hosoya, H., Fernandez-Pol, S., Gubatan, J., Ehlinger, Z., Lohman, C., Torres, A., Najidh, S., Kwang, A., Duran, G., Wright, C., Kennedy, V. E., Bharadwaj, S., Smith, et al
ELSEVIER.2024: 4846-4847
- **CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma**
Kramer, A., Srinagesh, H., Su, Y., Hamilton, M. P., Levine, K., Migliore, E., Denoble, K., Brown, A. K., Cunanan, K., Agarwal, N., Lohman, C., Mavroukakis, S., Bharadwaj, et al
ELSEVIER.2024: 2064-2066
- **Point-of-Care Bispectral Electroencephalogram (BSEEG) As a New Tool in Detecting Immune Effector Cell Associated Neurotoxicity (ICANS) in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T)**
Homsy, S., Seki, T., Nguyen, H., Shimura, A., Gorantla, N., Phuong, N., Ghalehsari, N., Velayati, A., Jeyakumar, N., Hamilton, M. P., Kennedy, V. E., Mikkilineni, L., Bharadwaj, et al
ELSEVIER.2024: 7134-7135
- **Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL**
Muffly, L., Ananth, S., Danley, L., Wagner, C., Kordek, D., Denoble, K., Fraser, A., Egeler, E., Molina, A., Ehlinger, Z., Desai, M., Daghigh, H., Tunuguntla, et al
ELSEVIER.2024: 680
- **Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged > 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)**
Lee, D., Bharadwaj, S., Rana, M. S., Jensen, A., Wang, W., Ghalehsari, N., Sahaf, B., Mallampet, J., Elkordy, S., Latchford, T., Arai, S., Johnston, L., Hosoya, et al
ELSEVIER.2024: 386-387
- **Investigating Treatment Kinetics and Local Response during and after Bridging Radiotherapy Prior to CAR-T Cell Therapy for Lymphomas**

Klebaner, D., Park, N., Marar, M., Frank, M. J., Hiniker, S., Hoppe, R. T., Schroers-Martin, J. G., Advani, R. H., Alizadeh, A. A., Bharadwaj, S., Miklos, D. B., Dahiya, S., Binkley, et al
ELSEVIER.2024: 7130-7131

- **Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma**
Hosoya, H., Jensen, A., Hovanky, V., Homsy, S., Cancilla, J. E., Patil, S., Kennedy, V. E., Bharadwaj, S., Smith, M., Shiraz, P., Frank, M. J., Dahiya, S., Arai, et al
ELSEVIER.2024: 2006-2007
- **CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up**
Kramer, A., Baird, J. H., Srinagesh, H., Egeler, E., Levine, K., Brown, A. K., Mavroukakis, S., Cunanan, K., Su, Y., Agarwal, N., Hamilton, M. P., Bharadwaj, S., Arai, et al
ELSEVIER.2024: 70-71
- **Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms**
Hamilton, M., Phillips, N., Lee, D., Ehlinger, Z., Kramer, A., Srinagesh, H., Good, Z., Kang, X., Olsen, M., Liu, C., Tian, F., Sworder, B. J., Hosoya, et al
ELSEVIER.2024: 96-97
- **PHASE 1 TRIAL RESULTS FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES TREATED WITH ORCA-T CELL THERAPY WITH REDUCED INTENSITY CONDITIONING AND SINGLE AGENT TACROLIMUS**
Villar-Prados, A., Sutherland, K., Negrin, R., Arai, S., Frank, M., Johnston, L., Lowsky, R., Miklos, D., Muffly, L., Dahiya, S., Rezvani, A., Sidana, S., Shiraz, et al
SPRINGER NATURE.2024: 287-288
- **Real-World Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients With Richter Transformation (RT) From the Center for International Blood and Marrow Transplant Research (CIBMTR)**
Mirza, A., Winter, A., Bharadwaj, S., Herrera, A. F., Iragavarapu, C., Palomba, M., Patel, S. S., Gharibo, M., Bernasconi, D., Krimmel, T., Liu, F., Roy, D., Pasquini, et al
CIG MEDIA GROUP, LP.2024: S347-S348
- **ALPHA2: A Phase 1b Study Evaluating the CD19 Allogeneic CAR T Cell Product Cemacabtagene Ansedegleucel (Cema-Cel) in Patients With Relapsed/ Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)**
Miklos, D., Bharadwaj, S., Holmes, H., Oluwole, O., Jallouk, A., Neelapu, S., Jain, N., Nath, R., Munoz, J., Bryan, L., De Vos, S., Eradat, H., Patel, et al
CIG MEDIA GROUP, LP.2024: S604
- **CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.** *Lancet (London, England)*
Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., Oak, J. S., Younes, S. F., Natkunam, Y., Hamilton, M. P., Su, Y. J., Agarwal, N., Chinnasamy, et al
2024
- **A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.** *Blood*
Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., Mavroukakis, S., Kuo, A., Cancilla, J., Sahaf, B., Agarwal, N., Kanegai, A. M., Kramer, et al
2024
- **Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.** *Journal for immunotherapy of cancer*
Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., Lee, D., Mallampet, J., Elkordy, S., Syal, S., Patil, S., Latchford, T., Sahaf, et al
2024; 12 (7)
- **Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR)**
Winter, A., Bharadwaj, S., Herrera, A., Iragavarapu, C., Mirza, S., Palomba, M., Patel, S. S., Gharibo, M., Bernasconi, D., Krimmel, T., Liu, F., Roy, D., Pasquini, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
- **CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.** *Blood advances*

- Hamilton, M. P., Craig, E., Gentile Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., Ehlinger, Z., Syal, S., Good, Z., Sworder, B., Schroers-Martin, J., Lu, Y., Muffly, et al
2024
- **CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.** *Leukemia*
Schultz, L. M., Jeyakumar, N., Kramer, A. M., Sahaf, B., Srinagesh, H., Shiraz, P., Agarwal, N., Hamilton, M., Erickson, C., Jacobs, A., Moon, J., Baggott, C., Arai, et al
2024
 - **Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient.** *EJHaem*
Lee, D., Goyal, A., Wang, W. L., Ananth, S., Lau, E., Binkley, M. S., Bharadwaj, S., Dahiya, S.
2024; 5 (1): 153-156
 - **Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma.** *Blood advances*
Nie, E. H., Su, Y. J., Baird, J. H., Agarwal, N., Bharadwaj, S., Weng, W. K., Smith, M., Dahiya, S., Han, M. H., Dunn, J. E., Kipp, L. B., Miklos, D. B., Scott, et al
2024
 - **CCL8/CCL13-producing tumor-associated macrophages linked to poor outcomes after CAR T cell therapy for LBCL.** *American Society of Hematology*
Mo, K. C., Yeh, C. Y., Hamilton, M. P., Spiegel, J., Desai, M., Ehlinger, Z., Reynolds, W. D., Yang, E., Ozawa, M. G., Chen, Y., Prabhu, S., Frank, M. J., Muffly, et al
2024
 - **TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas: Implications for Targeted Therapy.** *The American journal of surgical pathology*
Libert, D., Zhao, S., Younes, S., Mosquera, A. P., Bharadwaj, S., Ferreira, C., Natkunam, Y.
2023
 - **Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD.** *Blood advances*
Bader, C. S., Pavlova, A., Lowsky, R., Muffly, L., Shiraz, P., Arai, S., Johnston, L. J., Rezvani, A. R., Weng, W. K., Miklos, D. B., Frank, M. J., Tamaresis, J. S., Agrawal, et al
2023
 - **CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias**
Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., Tamaresis, J., Esfahani, M., Lu, Y., Olsen, M., Liu, C., Ehlinger, Z., Desai, et al
AMER SOC HEMATOLOGY.2023
 - **Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)**
Dahiya, S., Spiegel, J. Y., Lee, D., Mohammed, T., Lutfi, F., Goyal, A., Hana, C., Chavez, J. C., Ionescu, F., Frank, M. J., Bharadwaj, S., Sandoval-Sus, J., Beitinjaneh, et al
AMER SOC HEMATOLOGY.2023
 - **CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN- Cytokine Signature**
Srinagesh, H., Baird, J. H., Agarwal, N., Su, Y., Kramer, A., Reschke, A., Jeyakumar, N., Bharadwaj, S., Schultz, L., Ramakrishna, S., Davis, K. L., Sahaf, B., Feldman, et al
AMER SOC HEMATOLOGY.2023
 - **Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of Chimeric Antigen Receptor-T (CAR T) Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma (LBCL)**
Goyal, A., Bharadwaj, S., Lee, D., Lau, E., Hamilton, M. P., Jensen, A., Sahaf, B., Syal, S., Patil, S., Cancilla, J. E., Latchford, T., Weng, W., Smith, et al
AMER SOC HEMATOLOGY.2023
 - **Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)**
Bharadwaj, S., Lau, E., Goyal, A., Hamilton, M. P., Srinagesh, H., Jensen, A., Syal, S., Mallampet, J., Latchford, T., Sahaf, B., Weng, W., Smith, M., Maecker, et al
AMER SOC HEMATOLOGY.2023

- **Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection**
Ananth, S., Su, Y., Hamilton, M. P., Agarwal, N., Weng, W., Dahiya, S., Bharadwaj, S., Mallampet, J., Smith, M., Kong, K., Twoy, A., Miklos, D. B., Frank, et al
AMER SOC HEMATOLOGY.2023
- **Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucl (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)**
Bharadwaj, S., Lau, E., Hashmi, A., Hamilton, M. P., Jensen, A., Goyal, A., Marar, M., Lee, C., Ananth, S., Sahaf, B., Mallampet, J., Ehlinger, Z., Syal, et al
AMER SOC HEMATOLOGY.2023
- **Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus**
Villar-Prados, A., Meyer, E. H., Sutherland, K., Negrin, R. S., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Miklos, D. B., Muffly, L. S., Dahiya, S., Rezvani, A. R., Sidana, et al
AMER SOC HEMATOLOGY.2023
- **Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma.** *Blood cancer journal*
Sidana, S., Hosoya, H., Jensen, A., Liu, L., Goyal, A., Hovanky, V., Sahaf, B., Bharadwaj, S., Latchford, T., Arai, S., Leahy, S., Mei, M., Budde, et al
2023; 13 (1): 158
- **Idecabtagene vicleucl chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.** *Haematologica*
Sidana, S., Peres, L. C., Hashmi, H., Hosoya, H., Ferreri, C., Khouri, J., Dima, D., Atrash, S., Voorhees, P., Simmons, G., Sborov, D. W., Kalariya, N., Hovanky, et al
2023
- **Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance.** *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*
Younes, S., Zhao, S., Bharadwaj, S., Mosquera, A. P., Libert, D., Johnsrud, A., Majzner, R. G., Miklos, D. B., Frank, M. J., Natkunam, Y.
2023: 100256
- **Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.** *Journal of neuropathology and experimental neurology*
Nie, E. H., Ahmadian, S. S., Bharadwaj, S. N., Acosta-Alvarez, L., Threlkeld, Z. D., Frank, M. J., Miklos, D. B., Monje, M., Scott, B. J., Vogel, H.
2023
- **Idecabtagene Vicleucl Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience**
Sidana, S., Peres, L. C., Hashmi, H., Hosoya, H., Ferreri, C. J., Atrash, S., Khouri, J., Voorhees, P. M., Dima, D., Simmons, G., Kalariya, N., Hovanky, V., Bharadwaj, et al
AMER SOC HEMATOLOGY.2022: 10377-10379
- **Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects**
Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M., Good, Z., Sworder, B., Schroers-Martin, J., Liu, C., Severinsen, F., Hanson, P. J., Lu, Y., Lowsky, et al
AMER SOC HEMATOLOGY.2022: 7545-7547
- **The Development of Carhlh after Axicabtagene Ciloleucl Is Associated with Poor Outcomes**
Philip, S., Srinagesh, H. K., Hamilton, M. P., Gentile, C., Mina, A., Arai, S., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, R. S., Rezvani, A. R., Shiraz, P., Shizuru, et al
AMER SOC HEMATOLOGY.2022: 12775-12777
- **Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma**
Bharadwaj, S., Hamilton, M. P., Sahaf, B., Tamaresis, J., Patil, S., Hanson, P. J., Latchford, T., Arai, S., Johnston, L. J., Lowsky, R., Negrin, R. S., Rezvani, A. R., Shizuru, et al
AMER SOC HEMATOLOGY.2022: 10371-10373
- **Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease**

- Chin, M., Shizuru, J. A., Muffly, L., Shiraz, P., Johnston, L. J., Lowsky, R., Rezvani, A. R., Frank, M. J., Bharadwaj, S., Weng, W., Negrin, R. S., Miklos, D. B., Arai, et al
AMER SOC HEMATOLOGY.2022: 4788-4789
- **Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era**
Philip, S., Lowsky, R., Johnston, L. J., Arai, S., Meyer, E. H., Negrin, R. S., Rezvani, A. R., Shiraz, P., Shizuru, J. A., Sidana, S., Weng, W., Bharadwaj, S., Frank, et al
AMER SOC HEMATOLOGY.2022: 4825-4827
 - **Geriatrics assessment in older adults referred for hematopoietic cell transplantation.** *Journal of the American Geriatrics Society*
Sossenheimer, P. H., Bharadwaj, S., Johnston, L., Periyakoil, V. S.
2022
 - **Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with CD19 CAR T-cell lymphoma therapy**
Nie, E., Ahmadian, S., Bharadwaj, S., Acosta-Alvarez, L., Threlkeld, Z., Frank, M., Miklos, D., Born, D., Scott, B., Monje, M., Vogel, H.
OXFORD UNIV PRESS INC.2022: 464
 - **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.** *Transplantation and cellular therapy*
Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R., Rezvani, et al
2022
 - **Detection of Aberrant CD58 Expression in a Wide Spectrum of Hodgkin and Non-Hodgkin Lymphomas: Implications for CAR T Cell Resistance**
Younes, S., Libert, D., Zhao, S., Johnsrud, A., Bharadwaj, S., Majzner, R., Frank, M., Miklos, D., Natkunam, Y.
SPRINGER NATURE.2022: 1046-1048
 - **Detection of Aberrant CD58 Expression in a Wide Spectrum of Hodgkin and Non-Hodgkin Lymphomas: Implications for CAR T Cell Resistance**
Younes, S., Libert, D., Zhao, S., Johnsrud, A., Bharadwaj, S., Majzner, R., Frank, M., Miklos, D., Natkunam, Y.
SPRINGER NATURE.2022: 1046-1048
 - **Structural Racism is a Mediator of Disparities in Acute Myeloid Leukemia Outcomes.** *Blood*
Abraham, I. E., Rauscher, G. H., Patel, A. A., Pearse, W., Rajakumar, P., Burkart, M., Aleem, A., Dave, A., Bharadwaj, S., Paydary, K., Acevedo-Mendez, M., Goparaju, K., Gomez, et al
1800
 - **Significance of isolated deletion (20q) in donor cells after allogeneic hematopoietic cell transplantation** *LEUKEMIA & LYMPHOMA*
Nathan, S., Bharadwaj, S., Luke, K., Kalas, L., Katz, D. A., Hussain, M., Miller, I., Hsu, W., Shammo, J., Venugopal, P., Ustun, C.
2020; 61 (8): 2008-2011
 - **Gender and glaucoma: what we know and what we need to know** *CURRENT OPINION IN OPHTHALMOLOGY*
Vajaranant, T. S., Nayak, S., Wilensky, J. T., Joslin, C. E.
2010; 21 (2): 91-99